FDA advisers support GSK's RSV vaccine
GSK's vaccine for respiratory syncytial virus won the support of a key panel of U.S. regulatory advisers for use in people 60 and older, as the drugmaker races against Pfizer to bring to market the first vaccine for RSV.
Source: arkansasonline.com